tbuckley/cabot-search huggingface dataset:
Intravenous medications and green urine
Authors: P. Bowling
Journal: JAMA (1981)

<h3>To the Editor.—</h3> A 48-year-old man was admitted to the emergency room with vomiting, nausea, diarrhea, and abdominal pain. Physical examination, elevated serum and urine amylase values, and a history of alcohol abuse led to the diagnosis of acute pancreatitis. The patient was admitted to the hospital, and at approximately 8 AM on the morning of admission, the patient received intravenous (IV) butorphanol tartrate (Stadol) and IV promethazine hydrochloride (Phenergan). At 8 PM on the day of admission, the patient was first noted to be voiding green urine. At 10:30 PM on the day of admission, the patient was given IV cimetidine, 300 mg. On the second hospital day, the patient was given IV cimetidine, 300 mg at 4 AM, 1 AM, 4 PM, and 10 PM, and at 4 AM on the third hospital day. Thereafter the patient received cimetidine only by the oral route. The patient's urine continued
Dermatology
Authors: J. S. Dover
Journal: JAMA (1990)

In the treatment of benign vascular anomalies, the distinct advantages of the 577-nm pulsed dye laser over other treatment modalities, especially the extremely low risk of scarring, have enabled this laser to become the treatment of choice for many port-wine stains and telangiectasia in adults. More important, it is the treatment of choice for port-wine stains in children—an entity for which previously there existed no reasonably effective treatment. Of 36 port-wine stains treated in children with the pulsed dye laser, 34 cleared completely without adverse effect, while only 2 developed atrophic scarring.<sup>1</sup>By treating port-wine stains in early childhood (as early as 3 weeks of age), the psychological burden on the family and the child may be alleviated. Based on the same concept of producing preferential injury to skin structures by using brief and selectively absorbed laser pulses, pigmented skin structures rather than vascular structures can be selectively damaged.
Is bigger better for retrovirus conference?
Authors: R. Voelker
Journal: JAMA (1997)

ANYONE who's ever been to the International Conference on AIDS knows the meeting can be as much a pharmaceutical marketing platform and media carnival as it is a forum for new scientific and clinical data. Yet the thousands who attend the colossal conference, now held biennially, seem to lace up their running shoes as if they're about to embark on an endurance race, fully accepting the multitude of simultaneous scientific presentations, numerous pharmaceutical company— sponsored symposia, and walking, talking condoms as part of the scenery. So it's no surprise that scientists and physicians who study the human immunodeficiency virus (HIV) and treat patients with AIDS would like a more intimate meeting environment where they could discuss critical new data and treatment options without all the hoopla and distractions. <h3>New Appeal</h3> For a few years, at least, the Conference on Retroviruses and Opportunistic Infections served as such a venue. The meeting
DRAINAGE OF ABSCESS OF THE HAND
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Folia Clínica Internacional, Barcelona
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
San Francisco Bay Area institutions host AMA's seventh annual reporters conference
Authors: T. F. Kirn
Journal: JAMA (1988)

EVERY YEAR, at about the same time as an Indian summer, the American Medical Association (AMA) holds its annual science reporters conference. This year's, the seventh, was held with the cooperation of two of the San Francisco Bay Area's academic giants, Stanford University Medical Center and the University of California, San Francisco (UCSF). Last week's conference was held in a hotel on San Francisco's palm-lined Union Square, with 14 researchers and medical experts on the program. One afternoon was devoted to the topic of misconduct and fraud in medical research. (Please see accompanying article.) <h3>Scheduled to Speak</h3> The conference program included the following: Charles Epstein, MD, UCSF professor of pediatrics and biochemistry, has developed a model of Down's syndrome by endowing a mouse with three copies of the murine chromosome 16. Because this chromosome contains many of the same genes as the human chromosome 21, this trisomy mimics the trisomy
Effects on the Immune System Associated with Living near a Pesticide Dump Site
Authors: Marilyn F. Vine, Leonard Stein, Kristen Weigle, Jane Schroeder, Darrah Degnan, Chiu-Kit J. Tse, Carol Hanchette, Lorraine Backer
Journal: Environmental Health Perspectives (2000)

In this paper, we report results of the second phase of a larger study designed to evaluate the effects on the immune system of living near a Superfund site containing organochlorine pesticides, volatile organic compounds, and metals. Phase II was conducted to determine whether living near the site, consisting of six locations in Aberdeen, North Carolina, is associated with higher plasma organochlorine levels, immune suppression, or DNA damage. Each of 302 residents of Aberdeen and neighboring communities provided a blood specimen, underwent a skin test, and answered a questionnaire. Blood specimens were analyzed for organochlorine pesticides, immune markers, and micronuclei. Of 20 organochlorines tested, only DDE was detected in the blood of participants (except for one individual). Age-adjusted mean plasma DDE levels were 4.05 ppb for Aberdeen residents and 2.95 ppb (p = 0.01) for residents of neighboring communities. Residents of 40-59 years of age who lived within a mile of any site, but particularly the Farm Chemicals site, had higher plasma DDE levels than residents who lived farther away. Residents who lived near the Farm Chemicals site before versus after 1985 also had higher plasma DDE levels. Overall, there were few differences in immune markers between residents of Aberdeen and the neighboring communities. However, residents who lived closer to the dump sites had statistically significantly lower mitogen-induced lymphoproliferative activity than residents who lived farther away (p < 0.05). Residential location was not consistently associated with frequency of micronuclei or skin test responses. Although some statistically significant differences in immune markers were noted in association with residential location, the magnitude of effects are of uncertain clinical importance.
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
Authors: Kathy Miller, Javier Cortes, Sara A. Hurvitz, Ian E. Krop, Debu Tripathy, Sunil Verma, Kaveh Riahi, Joseph G. Reynolds, Thomas J. Wickham, Istvan Molnar, Denise A. Yardley
Journal: Journal of Clinical Oncology (2015)

TPS641 Background: Although HER2-targeted therapies such as pertuzumab and T-DM1 have improved patient outcomes, treatment resistance typically occurs. MM-302 is a HER2-targeted liposomal doxorubicin in development by Merrimack Pharmaceuticals. In a Phase 1 study, patients with HER2-positive metastatic breast cancer (MBC) were treated with MM-302 alone and in combination with trastuzumab with or without cyclophosphamide. MM-302 had an acceptable safety profile and promising efficacy was observed in patients not previously exposed to an anthracycline. Methods: Trial design: HERMIONE (NCT02213744) is a randomized Phase 2, two-arm, open-label trial designed to evaluate if MM-302 can address an unmet medical need in patients with anthracycline naïve, trastuzumab-, pertuzumab- and T-DM1-pretreated HER2-positive locally advanced breast cancer (LABC)/MBC. Patients are randomized 1:1 to receive MM-302 (30mg/m2, Q3W) plus trastuzumab (6mg/kg, Q3W) or chemotherapy of physician’s choice (vinorelbine, capecitabine, or gemcitabine) plus trastuzumab (6mg/kg, Q3W). Eligibility criteria: Centrally confirmed HER2-positive LABC/MBC, no prior anthracycline exposure, prior trastuzumab in any setting, prior pertuzumab and T-DM1 in the LABC/MBC setting, unlimited prior lines of therapy, ECOG 0-1 and LVEF ≥50%. CNS metastases are permitted if stable and without symptoms or steroids for 4 weeks. Specific aims: The primary endpoint is independently assessed progression free survival (PFS). Secondary endpoints include investigator assessed PFS, overall survival, response rate, safety and patient related outcomes. Statistics: 250 patients will be enrolled to observe 191 PFS events for 90% power to detect a Hazard Ratio of 0.625. The MM-302 arm will be compared to the control arm on the primary endpoint of PFS using a stratified log-rank test at one-sided 0.025 level. Accrual status: Recruitment began in July 2014 and is expected to be complete in late 2016. Sites will be open in the US, Canada and Western Europe. Clinical trial information: NCT02213744.
Abstract B07: Visualization of the mechanisms of metastasis within a biomimetic engineered tumor microenvironment encompassing a perfusable cylindrical 3D microvessel
Authors: Andrew D. Wong, Vanesa Silvestri, Andrew J. Ewald, Peter C. Searson
Journal: Cancer Research (2017)

Abstract Metastasis is responsible for the majority of cancer related deaths; however, many of the biological and physical details surrounding the critical steps (e.g. invasion and intravasation) are largely unknown, in part due to the difficulty in recapitulating and visualizing these dynamic processes. To elucidate these mechanisms, we have developed an in vitro model of invasion and intravasation that comprises tumor cells embedded within an extracellular matrix (ECM) surrounding an engineered microvessel. The microvessel is cylindrical, 150 μm in diameter, and lined with endothelial cells forming a functional barrier that is maintained under constant perfusion at a shear stress of 2-8 dyne cm-2. Using this biomimetic tumor-microvessel platform, we have previously visualized invasion and intravasation of single MDA-MB-231 breast cancer cells into the microvessel and escape into flow. Here, we present mechanistic details of intravasation from both single tumor cells (MDA-MB-231) and mouse mammary tumor organoids (MMTV-PyMT). For single cells, we observe a mitosis-mediated mechanism of intravasation where tumor cell entry into flow is prefaced by cell division at the ECM-vessel interface. For tumor organoids, we see vascular deformation and destabilization from growing tumors that impinge upon proximal vessels, and that bulk intravasation is mediated by shear stress and tumor cell adhesion. As we characterize the various ways in which tumor cells interact with the vessel endothelium and intravasate, we can explore strategies involving the tumor vasculature and clinically relevant drugs to inhibit critical steps in the metastatic cascade. Citation Format: Andrew D. Wong, Vanesa Silvestri, Andrew J. Ewald, Peter C. Searson. Visualization of the mechanisms of metastasis within a biomimetic engineered tumor microenvironment encompassing a perfusable cylindrical 3D microvessel. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B07.
Anatomical Studies of the Central Nervous System of Dogs Without Forebrain or Cerebellum.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insulin in the management of the diabetic surgical patient: continuous intravenous infusion vs subcutaneous administration
Authors: U. Taitelman
Journal: JAMA (1977)

A prospective randomized study comparing constant intravenous infusion of regular, low-dose insulin versus conventional subcutaneous administration of neutral protein Hagedorn (NPH) insulin in insulin-requiring patients undergoing orthopedic procedures under general anesthesia was undertaken. The degree of diabetic control was better in those receiving constant 2 units/hour of regular insulin than in those receiving two thirds of daily maintenance doses of NPH insulin. However, in two of eight patients receiving 2 units/hour, decreased insulin infusion rates and increased dextrose infusion rates were required to avoid hypoglycemia. Preoperative NPH insulin and 1 unit/hour insulin administration resulted in equivalent diabetic control. (<i>JAMA</i>237:658-660, 1977)
THE CORNELL PAY CLINIC
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.
Authors: Oliver A. Zill, Stefanie Mortimer, Kimberly C. Banks, Rebecca J Nagy, Darya Chudova, Coyt Jackson, Arthur Baca, Joseph Z. Ye, Richard Burnham Lanman, AmirAli Talasaz, Helmy Eltoukhy, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2016)

LBA11501 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, June 4, 2016, and in the Annual Meeting Proceedings online supplement to the June 20, 2016, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Wounded Eurydice
Authors: M. Therese Southgate
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The prognostic index in malignant melanoma
Authors: A. W. Kopf
Journal: JAMA (1978)

According to an article by Schmoeckel and Braun-Falco (<i>Arch Dermatol</i>114:871-873, 1978), the best method of predicting metastases from malignant melanoma was the prognostic index, which was defined as the product of tumor thickness (millimeter) and the number of mitoses per square millimeter. This index allowed the authors to predict with a high degree of accuracy those primary melanomas that later developed metastases. This potentially important observation has the great advantage of simplicity for the pathologist since all it requires is the determination of two values—tumor thickness and mitoses per square millimeter. However, it is likely that numerous factors will eventually be found to have added importance in prognosticating the outcome of primary malignant melanomas. Thus, factors such as type of melanoma (lentigo maligna melanoma, superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and mucosal melanomas), the site of the melanoma (head and neck, trunk, limbs, palms and soles, and
BOOK REVIEWS
Authors: N. E. FUSENIG
Journal: JNCI Journal of the National Cancer Institute (1990)

BOOK REVIEWS Get access Progress in Clinical and Biological Research, Volume 298. Skin Carcinogenesis: Mechanisms and Human Relevance. Thomas J. Slaga , Andre J. P. Klein-Szanto , R. K. Boutwell , Donald E. Stevenson , Hugh L. Spitzer , Bob D'Motto , eds. New York : Alan R. Liss, Inc. , 1989 , 424 pp. $84. NORBERT E. FUSENIG NORBERT E. FUSENIG German Cancer Research Center Institut fur Biochemie Im Nevenheimer Feld280 D-6900 Heidelberg 1 Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 2, 17 January 1990, Pages 147–148, https://doi.org/10.1093/jnci/82.2.147-a Published: 17 January 1990
Imaging Children
Authors: Jerry Kelleher
Journal: JAMA (1995)

This major new textbook of pediatric imaging breaks fresh ground in that it is a collaborative effort from some of the leading lights of the European subspecialty grouping, the European Society of Paediatric Radiology. Presented in two volumes, including a double index, it totals 2019 pages and weighs in at 7.5 kg. It is decidedly not intended for the pocket of the average white coat! Set out in a conventional way, with a total of 13 chapters devoted to the various body systems, it is encyclopedic in coverage. This reviewer has been unable to think of a significant disease process that is not mentioned and well covered. The chapters dealing with the cardiac, hepatobiliary, orthopedic, and central nervous systems are particularly excellent in content. For a book with 30 individual authors, the style is commendably uniform and readable and a great tribute to the editors. There is great variability in
Clinodactyly deformity simulating trisomy-18 hand malformation
Authors: D. E. Comings
Journal: JAMA (1970)

<h3>To the Editor.—</h3> In trisomy-18 syndrome the hand has a characteristic deformity. There is flexion of the fingers with overriding and medial deviation of the index and little fingers. The dermatoglyphics in these individuals is characterized by a high percentage of arches. A child had a hand deformity closely simulating that seen in trisomy-18 and an increased number of arches, but there were no other congenital defects and no chromosomal changes. The presence of a similar defect in the mother suggested an autosomal dominant mode of inheritance. <h3>Report of a Case.—</h3> A 6-week-old female child had the hand changes shown in Fig 1 and 2. There was clinodactyly of the index and fifth fingers which caused them to deviate medially and overlap the ring and middle fingers. The child could freely extend the fingers (Fig 2) indicating an absence of flexion contractures. The manner in which this deformity mimics that